RAB38 is a potential prognostic factor for tumor recurrence in non‑small cell lung cancer

Hsieh,Jia‑Juan; Hou,Ming‑Mo; Chang,John  Wen‑Cheng; Shen,Yung‑Chi; Cheng,Hsin‑Yi; Hsu,Todd

doi:10.3892/ol.2019.10547

RAB38 is a potential prognostic factor for tumor recurrence in non‑small cell lung cancer

Authors:
- Jia‑Juan Hsieh
- Ming‑Mo Hou
- John Wen‑Cheng Chang
- Yung‑Chi Shen
- Hsin‑Yi Cheng
- Todd Hsu
View Affiliations

Affiliations: Department of Bioscience and Biotechnology and Center of Excellence for the Oceans, National Taiwan Ocean University, Keelung 20224, Taiwan, R.O.C., Division of Hematology‑Oncology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 33305, Taiwan, R.O.C.
Published online on: June 28, 2019 https://doi.org/10.3892/ol.2019.10547
Pages: 2598-2604

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ras‑related protein Rab‑38 (RAB38) is a member of the Ras small G protein family that regulates intracellular vesicular trafficking. Although the expression of RAB38 is reportedly deregulated in several types of cancer, its role in tumor biology remains to be elucidated. In the present study, the expression of RAB38 was analyzed in tumor specimens from patients with non‑small cell lung cancer (NSCLC) with tumor recurrence within 4 years (Group R), and those remaining disease‑free following initial surgery (Group NR), by reverse transcription‑semi‑quantitative PCR and subsequent semi‑quantification using ImageJ v4.0 software. The results revealed that the expression of RAB38 in Group R and NR specimens was positively associated with tumor recurrence; a high expression level was also associated with poor survival rate in these patients. Using NSCLC cell lines, it was demonstrated that tumor cells with mutations in the active epidermal growth factor receptor (EGFR) gene expressed higher levels of RAB38 compared with those with the wild‑type gene by reverse transcription‑PCR and western blot analysis. Furthermore, following specific RAB38 gene knockdown by short hairpin RNA transfection, EGFR mutants exhibited markedly reduced invasiveness when compared with cells transfected with empty vector controls by Matrigel Transwell assays. These results suggest that RAB38 is an important prognostic factor in NSCLC, and may serve a critical role in NSCLC‑associated tumor metastasis.

View Figures

View References

1	Silvestri GA and Rivera MP: Targeted therapy for the treatment of advanced non-small cell lung cancer: A review of the epidermal growth factor receptor antagonists. Chest. 128:3975–3984. 2005. View Article : Google Scholar : PubMed/NCBI
2	Recchi C and Seabra MC: Novel functions for Rab GTPases in multiple aspects of tumor progression. Biochem Soc Trans. 40:1398–1403. 2012. View Article : Google Scholar : PubMed/NCBI
3	Osanai K and Voelker DR: Analysis and expression of Rab38 in oculocutaneous lung disease. Methods Enzymol. 438:203–215. 2008. View Article : Google Scholar : PubMed/NCBI
4	MAQC Consortium, ; Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, et al: The MicroArray Quality Control (MAQC) project shows interplatform reproducibility of gene expression measurements. Nat Biotechnol. 24:1151–1161. 2006. View Article : Google Scholar : PubMed/NCBI
5	Ho JR, Chapeaublanc E, Kirkwood L, Nicolle R, Benhamou S, Lebret T, Allory Y, Southgate J, Radvanyi F and Goud B: Deregulation of Rab and Rab effector genes in bladder cancer. PLoS One. 7:e394692012. View Article : Google Scholar : PubMed/NCBI
6	Dong W, Cui J, Yang J, Li W, Wang S, Wang X, Li X, Lu Y and Xiao W: Decreased expression of Rab27A and Rab27B correlates with metastasis and poor prognosis in colorectal cancer. Discov Med. 20:357–367. 2015.PubMed/NCBI
7	He H, Dai F, Yu L, She X, Zhao Y, Jiang J, Chen X and Zhao S: Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr. 10:231–242. 2002. View Article : Google Scholar : PubMed/NCBI
8	Shimada K, Uzawa K, Kato M, Endo Y, Shiiba M, Bukawa H, Yokoe H, Seki N and Tanzawa H: Aberrant expression of RAB1A in human tongue cancer. Br J Cancer. 92:1915–1921. 2005. View Article : Google Scholar : PubMed/NCBI
9	Culine S, Honore N, Closson V, Droz JP, Extra JM, Marty M, Tavitian A and Olofsson B: A small GTP-binding protein is frequently overexpressed in peripheral blood mononuclear cells from patients with solid tumours. Eur J Cancer 30A. 670–674. 1994. View Article : Google Scholar
10	Amillet JM, Ferbus D, Real FX, Antony C, Muleris M, Gress TM and Goubin G: Characterization of human Rab20 overexpressed in exocrine pancreatic carcinoma. Hum Pathol. 37:256–263. 2006. View Article : Google Scholar : PubMed/NCBI
11	Kotzsch M, Sieuwerts AM, Grosser M, Meye A, Fuessel S, Meijer-van Gelder ME, Smid M, Schmitt M, Baretton G, Luther T, et al: Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: Identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat. 111:229–240. 2008. View Article : Google Scholar : PubMed/NCBI
12	Tan PY, Chang CW, Chng KR, Wansa KD, Sung WK and Cheung E: Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol. 32:399–414. 2012. View Article : Google Scholar : PubMed/NCBI
13	Mori Y, Yin J, Sato F, Sterian A, Simms LA, Selaru FM, Schulmann K, Xu Y, Olaru A, Wang S, et al: Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res. 64:2434–2438. 2004. View Article : Google Scholar : PubMed/NCBI
14	Shibata D, Mori Y, Cai K, Zhang L, Yin J, Elahi A, Hamelin R, Wong YF, Lo WK, Chung TK, et al: RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomas. Int J Cancer. 119:801–806. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zippelius A, Gati A, Bartnick T, Walton S, Odermatt B, Jaeger E, Dummer R, Urosevic M, Filonenko V, Osanai K, et al: Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunol Immunother. 56:249–258. 2007. View Article : Google Scholar : PubMed/NCBI
16	Wang H and Jiang C: RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma. Oncol Rep. 30:2350–2356. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chang JW, Wei NC, Su HJ, Huang JL, Chen TC, Wu YC, Yu CT, Hou MM, Hsieh CH, Hsieh JJ, et al: Comparison of genomic signatures of non-small cell lung cancer recurrence between two microarray platforms. Anticancer Res. 32:1259–1265. 2012.PubMed/NCBI
18	Jäger D, Stockert E, Jäger E, Güre AO, Scanlan MJ, Knuth A, Old LJ and Chen YT: Serological cloning of a melanocyte rab guanosine 5′-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library. Cancer Res. 60:3584–3591. 2000.PubMed/NCBI
19	Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L, Exner C, Schäfer N, et al: Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol. 177:8212–8218. 2006. View Article : Google Scholar : PubMed/NCBI
20	Chen J, Wang M, Zu L, Li W, Wang W, Li Y and Liu H: Abstract 4966: Establishment and characterization of a paired human non-small cell lung cancer cell lines from primary cancer and metastasis lymph node. Cancer Res. 74:2014.
21	Wu CY, Tseng RC, Hsu HS, Wang YC and Hsu MT: Frequent down-regulation of hRAB37 in metastatic tumor by genetic and epigenetic mechanisms in lung cancer. Lung Cancer. 63:360–367. 2009. View Article : Google Scholar : PubMed/NCBI
22	Tzeng HT, Tsai CH, Yen YT, Cheng HC, Chen YC, Pu SW, Wang YS, Shan YS, Tseng YL, Su WC, et al: Dysregulation of Rab37-mediated cross-talk between cancer cells and endothelial cells via thrombospondin-1 promotes tumor neovasculature and metastasis. Clin Cancer Res. 23:2335–2345. 2017. View Article : Google Scholar : PubMed/NCBI
23	Subramani D and Alahari SK: Integrin-mediated function of Rab GTPases in cancer progression. Mol Cancer. 9:3122010. View Article : Google Scholar : PubMed/NCBI
24	Huck L, Pontier SM, Zho DM and Muller WJ: Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA. 107:15559–15564. 2010. View Article : Google Scholar : PubMed/NCBI
25	Morello V, Cabodi S, Sigismund S, Camacho-Leal MP, Repetto D, Volante M, Papotti M, Turco E and Defilippi P: β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene. 30:4087–4096. 2011. View Article : Google Scholar : PubMed/NCBI
26	Jeong BY, Cho KH, Jeong KJ, Park YY, Kim JM, Rha SY, Park CG, Mills GB, Cheong JH and Lee HY: Rab25 augments cancer cell invasiveness through aβ1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. Exp Mol Med. 50:e4352018. View Article : Google Scholar : PubMed/NCBI